Cite
HARVARD Citation
Dikopf, A. et al. (n.d.). A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. Expert opinion on drug safety. pp. 485-493. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Dikopf, A. et al. (n.d.). A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients. Expert opinion on drug safety. pp. 485-493. [Online].